Entasis lands first antibiotic approval eight years after spinning out of AstraZeneca
Almost eight years after spinning out AstraZeneca’s antibiotics pipeline, Entasis Therapeutics has landed its first approval.
The FDA approved its Xacduro, made up of sulbactam and durlobactam injections, as a treatment for pneumonia caused by difficult-to-treat bacteria strains known as Acinetobacter baumannii-calcoaceticus complex (A. baumannii) among adult patients. Particularly among already vulnerable hospitalized patients, these infections can be deadly.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.